Questions? Contact us at

Presentations & Posters

Development of Multi-omics Approaches to Evaluate NKG2D-ligand Dynamics and Anti-tumor Immune Responses during CAR-NK Treatment
Poster Presentation | AACR | April 2022

Immune Masking Strategies to Extend the Pharmacokinetics of Allogeneic Cell Therapies
Poster Presentation | AACR | April 2022

CBLB, CISH and CD70 Multiplexed Gene Knockout with CRISPR/Cas9 Enhances Cytotoxicity of CD70 CAR NK Cells and Provides Greater Resistance to TGF β for Cancer Immunotherapy
Poster Presentation | AACR | April 2022

Surveying Surface Antigens Expression in Multiple Myeloma Preclinical Models
Poster Presentation | AACR | April 2022

A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects with B-cell Malignancies
Poster Presentation | ASH | December 2021

A Combined Strategy of CD70 CAR Co-expression with Membrane-bound IL-15 and CISH Knockout Results in Enhanced NK Cytotoxicity and Persistence
Oral Presentation | SITC | November 2021

CISH Gene-knockout Anti-CD70-CAR NK Cells Demonstrate Potent Anti-tumor Activity Against Solid Tumor Cell Lines and Provide Partial Resistance to Tumor Microenvironment Inhibition
Poster Presentation | SITC | November 2021

Potentiating the Large-Scale Expansion and Engineering of Peripheral Blood-Derived CAR NK Cells for Off-the-Shelf Application
Poster Presentation | SITC | November 2021

KIR Haplotype Can Inform Donor Selection in the Production of Allogeneic Memory-Like CAR NK Cells for Clinical Application
Poster Presentation | SITC | November 2021

A Phase 1 Study of NKX101, an Allogeneic CAR Natural Killer (NK) Cell Therapy, in Subjects With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS)
Poster Presentation | ASH | December 2020

Preclinical evaluation of NKX019, a CD19-targeting NK cell
Poster Presentation | SITC | November 2020

A combination of CAR-NK and CAR-T cells results in rapid and persistent anti-tumor efficacy while reducing CAR-T cell mediated cytokine release and T-cell proliferation
Poster Presentation | AACR | June 2020

CRISPR-Cas9-gRNA RNP mediated gene knockout of TGFbR2 and CISH enhances CD19-CAR NK cell function and provides resistance to TGFb
Poster Presentation | AACR | June 2020

Co-expression of a CD19-OX40-CD3ζ CAR with membrane bound IL-15 enhances natural killer cell function
Poster Presentation | AACR | November 2019

Stimulatory cells plus IL-12 and IL-18 augments NK cell expansion, transduction, memory phenotype, and in vitro and in vivo CAR NK cytotoxicity & persistence
Poster Presentation | SITC | November 2019

Expanded and engineered NK cells for the treatment of hepatocellular carcinoma
Poster Presentation | AACR | July 2019

Expanded and engineered NK cells upregulate expression of activation and survival genes associated with increased cytotoxicity and persistence
Poster Presentation | AACR | March 2019

NK Cells Engineered to Express a Bispecific CD123/NKG2D Chimeric Antigen Receptor (CAR) and IL-15 As Off-the-Shelf Therapy for Acute Myeloid Leukemia
Poster Presentation | Keystone | March 2019

Co-expression of a chimeric NKG2D receptor with membrane bound IL-15 enhances natural killer cell function and long term persistence in vitro and in vivo
Poster Presentation | SITC | March 2018

Publications & References

Natural Killer Cells May Be Scaled and Engineered as a Next Generation, Off-the-Shelf Cell Therapy for Cancer
Cell & Gene Therapy Insights, Trager, October 2019

The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments
Front Immunol, Veluchamy et al, May 2017

Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma
Cancer Immunol Res , Kamiya, Chang, Campana, July 2016

Ex Vivo-Expanded Natural Killer Cells Demonstrate Robust Proliferation in Vivo in High-Risk Relapsed Multiple Myeloma Patients
J Immunother, Szmania et al, January 2015

Autonomous Growth and Increased Cytotoxicity of Natural Killer Cells Expressing Membrane-Bound interleukin-15
Blood, Imamura et al, August 2014

Clearance of Acute Myeloid Leukemia by Haploidentical Natural Killer Cells Is Improved Using IL-2 Diphtheria Toxin Fusion Protein
Blood, Bachanova et al, June 2014

A Chimeric Receptor With NKG2D Specificity Enhances Natural Killer Cell Activation and Killing of Tumor Cells
Cancer Res, Chang et al, March 2013

Natural Killer Cell Reprogramming With Chimeric Immune Receptors
Methods Mol Biol, Shimasaki, Campana, 2013

Cytotoxicity of Activated Natural Killer Cells Against Pediatric Solid Tumors
Clin Cancer Res, Cho et al, August 2010

Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells
Blood, Imai, Iwamoto, Campana, March 2008